Literature DB >> 23218693

Mucin-producing sweat gland carcinoma of the eyelid: diagnostic and prognostic considerations.

Ambika Hoguet1, David Warrow, James Milite, Steven A McCormick, Elizabeth Maher, Robert Della Rocca, David Della Rocca, Andrew Goldbaum, Tatyana Milman.   

Abstract

PURPOSE: To describe the clinical and pathologic characteristics of mucin-producing sweat gland carcinoma of the eyelid and to determine whether neuroendocrine differentiation is of prognostic significance.
DESIGN: Retrospective interventional case series.
METHODS: Search of the New York Eye and Ear Infirmary pathology database between 1990 and 2011 identified 16 patients with mucin-producing sweat gland carcinoma. Clinical, histopathologic, and immunohistochemical analyses were performed on all identified cases.
RESULTS: The patients presented with vascularized, focally cystic, nonulcerated eyelid margin lesions. Histopathologic evaluation showed that 4 lesions (25%) had a cystic, papillary, and solid growth pattern with an in situ component, 7 (44%) were pure invasive mucinous carcinomas, and 5 (31%) demonstrated both growth patterns. Immunohistochemical analysis of 15 tumors showed that pure cystic/papillary lesions had a significantly greater percentage of synaptophysin-immunoreactive cells (P = .036). There was no significant difference in the number of neuroendocrine markers expressed or in the intensity of immunostaining among the 3 different growth patterns. Re-excision for margin clearance was performed in 8 of 13 cases (61.5%). Two of 13 lesions recurred (15%); 1 of these was an in situ tumor with cystic morphology and neuroendocrine differentiation and the other was pure invasive mucinous carcinoma. None of the lesions metastasized.
CONCLUSIONS: Mucin-producing sweat gland carcinoma pathologically represents a continuum, from an in situ lesion to a classic, invasive mucinous carcinoma. Immunohistochemical evidence of neuroendocrine differentiation can be observed in all lesions and does not appear to have a prognostic significance, arguing against the utility of immunohistochemical subtyping of mucinous sweat gland carcinomas.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23218693     DOI: 10.1016/j.ajo.2012.09.030

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  7 in total

1.  Endocrine mucin-producing sweat gland carcinoma of the eyelid.

Authors:  Anne C Collinson; Michelle T Sun; Craig James; Shyamala C Huilgol; Dinesh Selva
Journal:  Int Ophthalmol       Date:  2015-09-15       Impact factor: 2.031

Review 2.  [Endocrine mucin-producing sweat gland carcinoma. three case reports with a brief review of the literature].

Authors:  A Rütten; T Mentzel; L Requena
Journal:  Pathologe       Date:  2014-09       Impact factor: 1.011

3.  [Mucinous sweat gland carcinoma of the eyelid].

Authors:  P L Müller; M C Herwig; F G Holz; K U Loeffler
Journal:  Ophthalmologe       Date:  2016-09       Impact factor: 1.059

4.  An Update on Endocrine Mucin-producing Sweat Gland Carcinoma: Clinicopathologic Study of 63 Cases and Comparative Analysis.

Authors:  Meghana Agni; Meisha L Raven; Randy C Bowen; Nora V Laver; Patricia Chevez-Barrios; Tatyana Milman; Charles G Eberhart; Steven Couch; Daniel D Bennett; Daniel M Albert; R Nick Hogan; Paul O Phelps; Hillary Stiefel; Norberto Mancera; Martin Hyrcza; Ami Wang; Christopher K H Burris; Eric A Steele; Ashley A Campbell; Heather D Potter; Mark J Lucarelli
Journal:  Am J Surg Pathol       Date:  2020-08       Impact factor: 6.298

5.  Primary Cutaneous Mucinous Carcinoma of the Eyelid.

Authors:  Katherine Smith; Jake Laun; Wilton Triggs; Wyatt G Payne
Journal:  Eplasty       Date:  2017-09-27

Review 6.  Endocrine mucin-producing sweat gland carcinoma (EMPSGC) of the eyelid: Clinicopathologic features, immunohistochemical findings and review of literature.

Authors:  Kaustubh Mulay; Vikas Menon; Sumeet Lahane; Mukesh Sharma; Santosh G Honavar
Journal:  Indian J Ophthalmol       Date:  2019-08       Impact factor: 1.848

Review 7.  Pathology of eyelid tumors.

Authors:  Jacob Pe'er
Journal:  Indian J Ophthalmol       Date:  2016-03       Impact factor: 1.848

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.